What is Lucigen?
Lucigen, based in Middleton, Wisconsin, is a provider of advanced molecular biology products and services. The company focuses on developing innovative solutions for complex challenges in DNA cloning, amplification, protein expression, and next-generation sequencing. By simplifying genomic research, Lucigen offers a comprehensive suite of cloning kits, competent cells, and enzymes designed to accelerate the completion of demanding molecular biology experiments for life scientists.
How much funding has Lucigen raised?
Lucigen has raised a total of $3.9M across 2 funding rounds:
Private Equity
$1.7M
Angel/Seed
$2.2M
Private Equity (2012): $1.7M, investors not publicly disclosed
Angel/Seed (2014): $2.2M, investors not publicly disclosed
What's next for Lucigen?
The company's history of securing major enterprise-level funding, including its latest strategic investment, suggests a trajectory focused on scaling operations and expanding its technological capabilities. This capital infusion is likely to fuel further research and development, enhance product offerings, and potentially broaden market reach. Lucigen appears poised for continued growth and innovation in the competitive genomics market.
See full Lucigen company page
